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Summary Neuroblastoma is a heterogeneous childhood tumour of the sympathetic nervous system, in which deletions of chromosomal
region lp and amplification of the MYCN oncogene correlate with aggressive tumour behaviour. However, the majority of neuroblastoma
tumours show neither of these aberrations, indicating that other chromosomal regions may be involved in tumorigenesis. Here, we report
findings of loss of heterozygosity (LOH) on chromosome 3. In our neuroblastoma material, nine of 59 (15.3%) tested tumours showed allelic
loss of chromosome 3p markers. We found significant clinical and biological differences between tumours with the loss of one entire
chromosome 3 vs tumours with partial loss in chromosome region 3p. All children with tumours with whole chromosome 3 loss are long-term
survivors, whereas all children with tumours showing partial 3p LOH have died from tumour progression. A consensus region found to be
deleted in all the tumours with 3p deletions was defined by markers D3S1286 and D3S1295, i.e. 3p25.3-p14.3, distal to the FHIT gene.
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Neuroblastoma is a neural crest-derived solid tumour in children.
The clinical course of these tumours varies greatly. Locali4d
stage 1 and 2 neuroblastoma usually have a good prognosis after
surgery only, whereas metastatic stage 4 neuroblastomas often
have a poor outcome despite intensive therapy. It is the general
opinion that at least one tumour-suppressor gene important for
neuroblastoma tumour formation is located in chromosomie region
1p36 (Brodeur, 1995) and that N-myc amplification plays a role in
some ofthese aggressive tumours (Fong et al, 1989). Even though
several neuroblastomas have deletions on chromosome lp and/or
N-myc amplification, they are far from all. We have earlier
presented data (Martinsson et al, 1995) showing that 26% of
primary neuroblastoma tumours in our material have lp deletions
(52% of stage 4 tumours) and 26% have N-myc amplification
(57% of stage 4 tumours). Thus, many neuroblastomas, also of
advanced stages 3 and 4, do not show these genetic aberrations. It
is, therefore, likely that additional genetic factors are involved in
the aetiology ofneuroblastoma development. A few other chromo-
somal regions, e.g. 4p (Caron et al, 1996), 1lq (Srivatsan et al,
1991), 14q (Suzuki et al, 1989) and 17q (Savelyeva et al, 1994;
Van Roy et al, 1994), in particular the NFl gene (Martinsson et al,
1997), have been shown to be deleted or rearranged in subsets of
different neuroblastoma materials. We recently presented data
showing that 3p deletions are frequent in our neuroblastoma mate-
rial (Hallstensson et al, 1997).
In this paper, we present clinical implications ofthe 3p deletions
and define two subgroups of neuroblastoma tumours, one with 3p
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partial deletions and an unfavourable outcome and one with whole
chromosome 3 loss and favourable outcome. Furthermore, we
show that the 3p region most frequently deleted is located distally
to the proposed tumour-suppressor gene FHIT (Ohta et al, 1996).
MATERIALS AND METHODS
Patient material
Primary tumourtissue and corresponding normal tissue (fibroblast
or blood sample) from 59 children with neuroblastoma of all the
different clinical stages were used. The tumours were staged
according to the International Neuroblastoma Staging System
criteria (INSS; Brodeur et al, 1988, 1993). The children were
treated according to national and international protocols with
surgery for all patients, chemotherapy for those with regional and
metastatic tumours (stage 3 and 4) and local irradiation for a minor
subset. Children with stage 4 disease who achieved remission were
given megatherapy followed by autologous bone marrow trans-
plantation. Twenty-three children died during follow-up (0-96
months from diagnosis, median 11 months), whereas the 36
surviving children have been followed for 3-119 months from
diagnosis (median follow-up 39 months). Survival probability for
the whole cohort was 58.7% ± 6.9% at 3 and 6 years from
diagnosis. Detailed information on children with chromosome
3 aberrations and summarized data on the other patients in the
study are given in Table 1. Additional details on patient
characteristics,presence/absence of aberrations of chromosome
lp and amplification of N-myc have been presented earlier
(Martinsson et al, 1995). In the present material, 15 tumours
showed Ip LOH, and 14 were amplified for N-myc (11 tumours
showed both these aberrations).
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Analysis of PCR-based polymorphisms
Polymerase chain reaction (PCR)-based polymorphic markers and
the primer sequences used in the study were derived from the
Genethon (Dib et al, 1996) and the CHLC (http://www.chlc.org/)
genetic maps. The marker loci for chromosome 3 used and their
relative genetic positions are shown in Figure 1. Map data for
Genethon markers were derived from Dib et al (1996) (Figure 1),
and map data for non-Genethon markers were derived from the
same source (Table 5 in Dib et al, 1996). The PCR conditions used
were according to our previously published procedures
(Martinsson et al, 1995). DNA from normal tissue and from
tumour tissue of each patient were run in adjacent lanes and the
patterns were compared. Three different patterns were obtained:
(1) loss of heterozygosity (LOH); the patient's normal DNA was
heterozygous and one of the alleles was missing in the tumour
DNA; (2) no loss ofheterozygosity (no LOH); the patient's normal
DNA was heterozygous and the tumour DNA was identical; and
(3) non-informative (n.i.); the patient was homozygous for the
polymorphism in both normal and tumour DNA.
STS mapping of YAC clones
STS mapping of 3p markers has been presented elsewhere
(Aburatani et al, 1996). For mapping of the most distally located
exon ofthe FHIT gene (exon 10), the Genethon Mega yeast artificial
chromosome (YAC) library (Cohen et al, 1993) was screened by
PCR, with the following primer pair: HA738 (intron 9 forward),
5'-ATGTTAGAATCATAAGGCC'lTTG-3' and HA691 (exon 10
reverse), 5'-AGGCTGCCGAATAAGGAGAC-3', nucleotides
1054-1035. The screening DNA pools were provided by Riken,
Tsukuba Life Science Center(Ibaragi, Japan). Physical mapping data
for markers in the 3p14.2 region were derived from previously
published data (Aburatani et al, 1996) and the Whitehead database
(internet address: http://www-genome.wi.mit.edu) contig WC-3.10.
Statistical analysis
The probability ofsurvival (± standard error) was calculated using
the product limit method of Kaplan and Meier (Kaplan and Meier,
1958) and compared using the Mantel-Haenszel log rank test. The
Fisher exact test was used for the analysis of 2 x 2 tables. The
Wilcoxon Mann-Whitney test was used when two groups were
compared and Kruskal-Wallis analysis was used for the compar-
ison ofseveral groups.
Ethical approval
The present study was approved as a multicentre study by the
ethics committees ofthe Uppsala University, Karolinska Institute,
Stockholm and the University ofGothenburg.
RESULTS
LOH analysis with chromosome 3 markers
DNAsfrompatients with neuroblastoma (n =59) were subjected to a
LOH study using microsatellite markers on different locations on
chromosome 3. The markers used and their genetic locations are
shown in Figure 1. Nine tumours (15.3%) showed LOH for at least
twochromosome 3 markers. Ofthese, fourtumours showedLOHfor
all informative markers used, indicating that a complete copy of
chromosome 3 was lost in the tumour. In contrast, five tumours
detected loss ofdistal 3p markers only, while 3q markers and more
proximal 3p markers were retained in two copies. LOH for chromo-
some 3 was found in neuroblastomas of all the different clinical
stages. A particular region on 3p was deleted in all nine tumours.
This region couldbe definedby the deletionpatterns in two tumours.
One of the tumours (ST102) had a breakpoint between markers
D3S1768 and D3S1295. This defines the proximal border of the
smallest region ofoverlap (SRO). The distal border was defined by
an interstitial deletion in one tumour(189). Thedistal deletion break-
point for this tumour was between markers D3S1286 and D3S1768,
and the proximal breakpoint was between markers D3S1766 and
D3S1598. Taken together, these data give a smallest region of
overlap (SRO) ofdeletion defined distally by marker D3S1286 and
proximally by D3S1295, i.e. 3p25.3-p14.3 (Figures 1 and 2).
Localization of the FHIT gene relative to the 3p SRO in
neuroblastomas
In order to localize the most telomeric part of the FHIT gene, i.e.
exon 10, relative to the deletions in the neuroblastomas, we
performed STS mapping vs the CEPH Mega YAC library. YACs
Table 1 Clinical and biological features of the neuroblastoma patients used in the study
3p and 3q LOH Distal 3p LOH No LOH for chromosome LOH for 1p but not
3 or 1 chromosome 3
n 4 5 40 10
Patient no 181 ST107 162 153 ST99 121 174 ST102 189
Sex F F M F F M F M M 20=F, 20=M 7=F, 3=M
Agea 122 10 0 11 35 72 50 15 30 14.5 (0-159), median (range) 15 (5-52)
Stageb 1 1 4S 3 3 2A 4 4 4 8=1, 8=2, 9=3, 12=4, 3=4S 10=4
1pLOH - - - - + + + + + 40- 10+
NMAc - - _ _ _ - + + + 34-, 3+, 3 ND 2-,8+
Outcomed NED NED NED NED DOD DOD DOD DOD DOD 27 NED, 10 DOD, 3 AWD 2 NED, 8 DOD
Survivale 32+ 24+ 52+ 57+ 10 96 6 11 17
Remarks' NF1
aAge at diagnosis in completed months; bstage 1, 2, 3, 4 and 4S according to INSS; cNMA, N-mycamplification, positive if > three copies per haploid genome,
ND, not done; dNED, no evidence of disease, DOD, dead of disease, AWD, alive with disease; eSurvival in completed months from diagnosis until death or last
follow-up (+); 'NF1 phenotype with homozygous deletion of the NF1 tumour-suppressor gene in the tumour (Martinsson et al, 1997).
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Figure 1 Summary of patients displaying LOH for chromosome 3 markers.
To the left is a genetic map of markers used in the study. Centimorgan
distances are indicated between markers. Identification number, stage and
outcome are displayed at the top. N, no evidence of disease; D, dead of
disease. The LOH pattern is shown for each patient and marker. (0) No loss
of heterozygosity; (0) loss of heterozygosity; -, non-informative marker; blank
regions, not done. Areas of deletion are shaded dark grey and areas of no
deletion are white; undefined areas are shaded light grey. The smallest
region of overlap of deletion (SRO) is indicated to the left
positive for FHIT exon 10 were 958-E-3, 958-H-12, 958-E-12,
768-A-7, 944-H-10 and 768-D-2. When comparing our data with
those from the region of interest from the Whitehead human
physical map project, the following combined order could be
obtained for selected markers: 3pter-D31295-D3S1592-
D3S1766-(D3S1313-D3S1547)-FHITexonI0-D3S1300/FHIT-
intron5-D3S1312-D3S1600-3cen.
Correlation of patterns of chromosome 3 LOH with
1p LOH, N-myc amplification, clinical features and
prognosis
Two distinct patterns of chromosome 3 aberrations were found in
neuroblastomas showing either acomplete loss ofone copy (n = 4)
or LOH restricted to distal 3p markers only (n = 5). Tumours with
these different patterns showed significant clinicobiological char-
acteristics (Table 1). Distal 3p LOH was only detected in tumours
with concomitant LOH for lp (5/15, P = 0.0006). Three out offive
of these tumours were N-myc amplified (vs 0/4, P = 0.059), and
there was a non-significant trend to more unfavourable clinical
stages in these children with distal 3p LOH compared with those
with complete chromosome 3 LOH (three out offour ofmetastatic
INSS stage 4 vs 0/4, P = 0.12). There were no significant differ-
ences with regard to sex. All children with distal 3p LOH were
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KFigure 2 LOH analysis for chromosome 3 markers of the normal DNA (N)
and tumour DNA (T) in patients 162,181, STi 02 and 189. Markers used are
indicated on the left, and alleles detected are displayed under each
photograph. (A) Analyses of patients with favourable outcome; (B) analyses
of patients with unfavourable outcome
older than the median age at diagnosis (14.5 months), whereas
three out of four with total 3 LOH were below one year of age
(P = 0.048).
All children with acomplete loss ofone chromosome 3 copy are
alive and well 2 years or more after diagnosis, contrasting with the
group with distal 3p LOH, in which all have died during follow-up
(P = 0.008). Survival probability according to Kaplan-Meier in
these two groups at 3 years as 100% and 20% (±17.9%) respec-
tively (P = 0.026, x2 = 4.941, d.f. = 1, Mantel-Haenszel log rank
test). Survival probability for children with neuroblastomas
without detected chromosome 3 aberrations was 59.3% ± 7.6%
between the two groups of children with detected chromosome 3
aberrations (P = 0.019, x2 = 7.956, d.f. = 2).
As distal 3p LOH was only found in tumours with lp LOH, we
compared subsets of children with tumours showing lp LOH
with and without 3p LOH. LOH for 3p correlated with older age
(P < 0.05) and was found in non-metastatic tumours (2/5 vs 0/10,
P = 0.095), but there was no difference in survival probability
(P = 0.78). All tumours with a complete 3 LOH had a triploid
DNA content in tumour cells (data not shown).
DISCUSSION
Two lines ofevidence have indicated that genes on chromosome 3p
may be important in the development and/or progression of neuro-
blastoma tumours. First, we performed a genome-wide scan for loss
of heterozygosity (LOH) with polymorphic markers in a subset of
different-staged neuroblastomas to get an overview of which
chromosomal region, if any, in addition to chromosomal region lp
(Martinsson et al, 1995), would be commonly deleted in our
material. Some regions frequently found by other authors to be
involved in deletion were not frequently deleted in our neuro-
blastoma material (Hallstensson et al, 1997). Instead, we found that
chromosome 3 loci were deleted at relatively high frequency.
Secondly, we performed representational difference analysis (RDA)
in order to obtain clones selectively lost in neuroblastoma tumours
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(Hallstensson et al, 1997). No clones homozygously lost were
obtained intheexperiments. However, hemizygously deletedclones,
i.e. clones resulting fromLOH ofchromosomal regions, were found.
On detailed analysis of these clones, we found that a large fraction
mapped to chromosome 3p (Hallstensson et al, 1997). On these
grounds, a larger, more detailed study was made in orderto evaluate
the extent ofdeletions on chromosome 3 in neuroblastomas.
We found that 15.3% of neuroblastomas in our material
displayed 3p LOH (Figures 1 and 2). This is the third most
common genetic aberration in our material, after lp LOH and N-
myc amplification (Martinsson et al, 1995). In the genome-wide
scan for LOH, we found the 'background level' of LOH in our
material to be low (Hallstensson et al, 1997). The smallest region
of overlap of chromosome 3 deletions in the tumours was distally
defined by marker D3S1286 and proximally defined by marker
D3S1295, i.e. 3p25.3-14.3 (Figures 1 and 2). A striking feature in
the 3 LOH pattern ofthe analysed tumours was that two clinically
distinct subgroups could be discerned: (1) a group of neuro-
blastomas with loss ofa complete chromosome 3 associated with a
favourable outcome; and (2) a group of neuroblastomas with
partial 3p loss in which all patients had a poor outcome (Table 1).
These data add further to the picture of neuroblastoma as being
a disease with large clinical heterogeneity related to specific
features on the molecular level (Brodeur, 1995). Thus, favourable
tumours prone to spontaneous differentiation and / or regression
often show a triploid karyotype without structural abnormalities,
suggesting whole chromosomal gains or losses. Indeed, our data
show that a subset of favourable tumours had lost one complete
chromosome 3 and probably duplicated the other retained allele
(Figure 2). On the other hand, unfavourable neuroblastomas are
often near-diploid, harbouring structural genetic aberrations
presumed to alter the function ofoncogenes or tumour-suppressor
genes specifically. The present subset of five tumours with distal
3p LOH associated with poor prognosis indicates the presence of
an additional tumour-suppressor locus involved in the tumorigen-
esis of aggressive neuroblastomas. Furthermore, we hypothesize
that this subset of unfavourable tumours may be the result of a
multistep tumorigenesis involving the loss of tumour suppressors
at lp and 3p in all five cases. In addition, one tumour had lostboth
copies ofthe NFl tumour suppressor (Martinsson et al, 1997) and
three other tumours showed amplification ofthe N-myc oncogene.
The results in the present study show the association between
specific aberrations of chromosome 3 and prognosis in neuroblas-
toma, with pooroutcome in all children having a tumour with distal
3p LOH. However, based on this limited material, we cannot
suggest the analysis ofchromosome 3 for prognostic evaluation of
individual patients, as there are a number of other well-character-
ized prognostic indicators useful for risk assessment of neuroblas-
tomapatients (Castleberry et al, 1997). Pooroutcome in the present
material was significantly associated with recognized risk factors,
such as age over 1 year (P = 0.007), metastatic stage 4, amplifica-
tion ofN-myc and lp LOH (all P < 0.001 in univariate analysis).
A few cases ofchromosome 3 aberrations in neuroblastoma have
been reported earlier: one patient with adup3q syndrome (Maier and
Beck, 1992) and one fetus with neuroblastoma that showed a partial
dup3q, unbalanced translocation 3;10 (Qureshi etal, 1994). The case
in these duplicate syndromes is often that one entire chromosome is
duplicated and the other is missing except for one remaining part, in
this case 3q. This means that, indup3q, onecopy of3pis missing and
the other is duplicated. This is in agreement with our results. In the
tumour DNA of some of our patients showing LOH, the remaining
allele gave a stronger signal than it did in the corresponding normal
DNA, although the same amount of genomic DNA had been used
(for representative analyses see Figure 2). This can indicate that the
LOH inthesetumours is accompaniedbythe addition ofoneormore
copies oftheretained allele. Ithas notbeen possible to perform cyto-
genetic analysis ofthese tumours to confirm these data.
Homozygous and heterozygous deletions in this region on chro-
mosome 3 have frequently been detected in a number of different
cancers, e.g. lung cancer (Roche et al, 1996) and breast cancer
(Buchhagen et al, 1994). Several genes with potential tumour-
suppressing activity have been shown to locate to this region.
Recently, the FHIT gene, which spans the 3:8 translocation break
in a renal cell carcinoma (Ohta et al, 1996), was isolated and
cloned. It is known that the polymorphic marker D3S1300 is
located in intron 5 within the FHIT gene itself (Ohta et al, 1996).
The tumour with the most distal deletion, ST102 (Figure 1), has a
deletion ofmarker D3S1768 as well as more distal markers, while
D3S1295 and markers proximal to it have both alleles retained.
D3S1295 is clearly distal to D3S1300, indicating that the deletion
in ST102 is distal to the FHIT gene. The tumour with the second
most distal deletion, 174, has two copies retained for marker
D3S1766, while one copy of D3S1295 is lost in the tumour
(Figure 1). The FHIT gene is reported to be very large and distrib-
uted over at least 500 kb ofgenomic DNA (Ohta et al, 1996). The
most telomeric ofthe FHIT exons (exon 10) has not to our knowl-
edge been mapped previously. Therefore, its location relative to
marker D3S1766 was not known. Using STS mapping to the
CEPH Mega YAC library, we showed that the order ofthe critical
markers is 3pter-D3S1766-(D3S1313-D3S1547)-FHITexonlO-
D3Sl300/FHITintron5-3cen. Thus, marker D3S1766, which is
retained in tumour 174, is clearly distal to the most distal FHIT
exon. Therefore, the deletion in tumour 174 also maps distal to the
FHIT gene. The three remaining tumours with distal 3p deletions
had LOH patterns indicating that FHIT may be within the deletion.
In one case, ST99, the deletion breakpoint is in or proximal to the
FHIT gene. The fact that the 3p SRO in neuroblastoma tumours is
distal to the FHIT gene may indicate that another gene distal to
FHIT is critical for neuroblastoma tumorigenesis. This also
pertains to other cancers with 3p aberrations.
Inconclusion, wehavedetected ahighincidence ofchromosome
3 LOH in neuroblastoma tumours, with a shortest region ofoverlap
of deletions between markers D3S1286 and D3S1295. In at least
two tumours, the deletions map distal to the proposed tumour-
suppressor gene FHIT located in 3pl4.2. Tumours withdeletions of
parts of 3p only were associated with a poor prognosis, whereas
tumours with loss of a complete copy of chromosome 3 had a
favourable outcome. A gene on chromosome region 3p, located
distal to FHIT, may be involved in neuroblastoma tumorigenesis.
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